Erschienen in:
01.02.2013 | Case Report
Severe EBV hepatitis treated with valganciclovir
verfasst von:
R. Pisapia, A. Mariano, A. Rianda, A. Testa, A. Oliva, L. Vincenzi
Erschienen in:
Infection
|
Ausgabe 1/2013
Einloggen, um Zugang zu erhalten
Abstract
We describe the case of an 18-year-old immunocompetent male patient with severe hepatitis during primary Epstein–Barr virus infection, treated with oral valganciclovir. During the initial therapy with corticosteroids, the patient’s clinical condition and liver function worsened, so we decided to add oral valganciclovir for its good bio-availability and previous encouraging experiences in different clinical settings, with rapid resolution of the symptoms.